research 1449 PROSTATE CANCER PATIENTS WITH METABOLIC SYNDROME SHOWED LOW GRADE GLEASON SCORE WHEN DIAGNOSED ON BIOPSY
Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
Search
for
Sort by
Research
720-750 / 1000+ results 
research Prostate Specific Antigen in Different Dermatoses Associated with Polycystic Ovary: Review Article
PSA might help diagnose PCOS and related skin issues, but more research is needed.
research Association between prostate‐specific antigen and serum testosterone: A systematic review and meta‐analysis
Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
research Relationship of Serum Prostate Specific Antigen with Hirsutism in Women Having Polycystic Ovary Syndrome Belonging to the Province of Khyber Pakhtunkhwa, Pakistan
Higher PSA levels are linked to more hirsutism in women with PCOS.
research Impact of baseline PSA level on quality of life measures of general health and sexual satisfaction/drive in men with BPH treated with finasteride or placebo
Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
research NEURONAL MIMICRY AS A RESISTANCE PHENOTYPE IN CANCER CELLS
Low dose finasteride causes only small changes in PSA levels in older men with BPH.
research 1262 ONE YEAR FINASTERIDE THERAPY IN MEN WITH A SERUM PSA GREATER THAN 4 NG/ML WHO HAD UNDERGONE REPEAT BIOPSY
Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
research Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women1
Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
research Effect of finasteride on prostate-specific antigen
Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
research Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
research 174 Changes in urine androgen and PG levels during finasteride treatment
Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.
research Editorial comment 1
Finasteride may reduce prostate cancer risk.
research L’étude PCPT
research Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.
research Le point de vue du pathologiste concernant l’étude PCPT
research Effect of Low-Dose Finasteride on Serum PSA Concentrations
Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
research [Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow].
research Enzyme-linked immunosorbent assays for doping control of 5α-reductase inhibitors finasteride and dutasteride
New tests detect finasteride and dutasteride in urine quickly and easily.
research MP09-17 METHYLATION OF SRD5A2 IN THE BLOOD AS A NOVEL BIOMARKER TO PREDICT SENSITIVITY TO 5-ARI TREATMENT
SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
research Contrast-Enhanced Ultrasound (CEUS) Evaluation of Canine Prostatic Hyperplasia before and after Osaterone Acetate Therapy: Preliminary Results
Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.
research Plasma androsterone/epiandrosterone sulfates as markers of 5α-reductase activity: Effect of finasteride in normal men
Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
research 1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY
PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
research 1452 DETECTION RATE OF CLINICALLY INSIGNIFICANT PROSTATE CANCER INCREASES WITH REPEATING PROSTATE BIOPSIES
More prostate biopsies increase the chance of finding cancers that may not need treatment.
research 412 DETECTION OF CIRCULATING PROSTATE CANCER CELLS BY MEANS OF AN ANTIBODY-CONJUGATED NANOPARTICULAR BIOSENSOR
The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
research Biochemical predictor for polycystic ovary syndrome
The uric acid to creatinine ratio is a strong indicator for diagnosing PCOS.
research Patients with a large prostate show a higher prevalence of androgenetic alopecia
Large prostate patients more likely to have hair loss.
research IMPACT OF LOW DOSE FINASTERIDE FOR THE TREATMENT OF ANDROGENIC ALOPECIA ON SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN PARTICIPATED IN POPULATION-BASED SCREENING FOR PROSTATE CANCER
Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
research Level-1 Data From the REDUCE Study and the PCPT Data
Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
research Faculty Opinions recommendation of Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial.
Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
research L'etude PCPT : regards d'un urologue intéressé
Finasteride may reduce prostate cancer risk.